Funded Biotechnology Startups in Ann Arbor
Ann Arbor's biotechnology sector shows consistent funding activity across this 12-company sample, with rounds dating from July 2021 through June 2025.
Ann Arbor's biotechnology sector shows consistent funding activity across this 12-company sample, with rounds dating from July 2021 through June 2025. Capital deployment spans a wide range — from $2M each for Evoq Therapeutics (August 2024) and Newhaptics via grant (September 2022) to a $225M post-IPO equity raise by Esperion in December 2021. Strata Oncology's $90M Series C (July 2021) and ONL Therapeutics' $65M Series D (September 2024) are the two largest venture-stage closes in the set.
Six of the twelve entries carry "Series Unknown" or "Venture - Series Unknown" labels, including Akadeum Life Sciences ($20M, June 2025), Upkara ($9M, April 2023), and Spike Neuro ($3M, June 2025). Two companies — Endra and Esperion — raised post-IPO equity, indicating they had already completed public listings before these transactions. The most recent activity falls in June 2025, when both Akadeum Life Sciences and Spike Neuro closed rounds within the same month.
Most recent rounds
12 shownRelated listings
Frequently asked
What are the largest disclosed rounds among these Ann Arbor biotech companies?
Esperion leads at $225M via post-IPO equity (December 2021), followed by Strata Oncology's $90M Series C (July 2021) and ONL Therapeutics' $65M Series D (September 2024). These three rounds account for the clear majority of disclosed capital across the twelve entries.
How common are unclassified round types in this segment?
Six of the twelve entries are labeled "Series Unknown" or "Venture - Series Unknown," and NOTA Labs did not disclose an amount at all. Formally classified venture rounds — Series B, C, and D — appear in only three entries: HYGIEIA, Strata Oncology, and ONL Therapeutics respectively.
Do any of these companies appear to have already gone public?
Yes. Esperion raised $225M through post-IPO equity in December 2021, and Endra raised $9M through the same structure in April 2022, confirming both had completed IPOs before these transactions.
What does the lower end of the deal size range look like here?
Evoq Therapeutics (Series Unknown, August 2024) and Newhaptics (grant, September 2022) each raised $2M — the smallest disclosed amounts in the set. Spike Neuro ($3M, June 2025) and Genomenon ($6M, May 2024) are the only other sub-$10M entries with disclosed figures.
Is there any non-equity funding in this dataset?
One entry — Newhaptics in September 2022 — is classified as a grant, receiving $2M. All other disclosed-amount rounds in this set involve equity or post-IPO equity structures.
How current is the funding activity shown?
The two most recent rounds both closed in June 2025 — Akadeum Life Sciences at $20M on June 3 and Spike Neuro at $3M on June 29. The oldest entry in this view is Strata Oncology's $90M Series C from July 2021.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.